Treatment Research

The articles below are listed in chronological order, newest to oldest.

Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss (Zhu et al., 2023)

In Vitro Effects of Mitochondria-Targeted Antioxidants in a Small-Cell Carcinoma of the Ovary of Hypercalcemic Type and in Type 1 and Type 2 Endometrial Cancer (Castelôa et al., 2022)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade (Romero et al., 2021)

SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy (Mardinian et al., 2021)

Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type (Ji et al., 2020)

The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer (Soldi et al., 2020)

Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer (Xue, Meehan, Fu, et al., 2019)

CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary (Xue et al., 2019)

Novel Genetic Marker in Ovarian and Lung Cancers

Ponatinib shows potent antitumor activity in small cell carcinoma of the ovary hypercalcemic type (SCCOHT) through multi-kinase inhibition (Lang et al., 2018)

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer.

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade (Jelinic et al., 2018)

Histone deacetylase inhibitors synergizes with catalytic inhibitors of EZH2 to exhibit anti-tumor activity in small cell carcinoma of the ovary, hypercalcemic type (Wang et al., 2018)

The histone methyltransferase EZH2 is a therapeutic target insmall cell carcinoma of the ovary, hypercalcaemic type (Wang et al., 2017)

SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment (Otte et al., 2016)

In vitro and in vivo therapeutic approach for a small cell carcinoma of the ovary hypercalcaemic type using a SCCOHT-1 cellular model (Otte et al., 2014)